Solbec Pharmaceuticals (ASX:SBP) has received orphan drug designation from the US Food and Drug Administration for its lead anti-cancer compound Coramsine for the treatment of high risk stage II, stage III and stage IV melanoma.

Australian biotech firms are celebrating Christmas early, unwrapping multi-million dollar AusIndustry Commercial Ready grants from the federal government in the lead-up to the holiday season.

Biotech shares bucked the trend during the month of October - the Intersuisse biotechnology index gained 6.6 per cent in contrast to the All Ordinaries and the Nasdaq Biotech Index, which fell by 3.9 per cent and 3.8 per cent respectively.

Solbec Pharmaceuticals (ASX:SBP) has received orphan drug designation from the US Food and Drug Administration for its lead anti-cancer compound Coramsine for the treatment of metastatic renal cell carcinoma (mRCC).

Southern Cross Equities biotech analyst Stuart Roberts was behind the recent DNA, Devices and Dealers conference in Sydney. Here, he explains his passion for hanging out with biotech's true believers.

Solbec Pharmaceuticals (ASX:SBP) has selected malignant melanoma and metastatic renal cell carcinoma (mRCC) as the first two tumour types for multiple target activity phase II trials of its lead compound Coramsine in the treatment of advanced tumours.

Perth-based Solbec Pharmaceuticals' (ASX:SBP ) managing director, Stephen Carter, has resigned.

Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent giving the company the monopoly right to prevent others from isolating the rhamnose binding protein receptor of its lead compound Coramsine.

Solbec Pharmaceuticals' (ASX:SBP) devil's apple-derived drug Coramsine (SBP002) has met the primary endpoint of safety and tolerability for the two-hour infusion cohort of its single agent phase I clinical trial for advanced solid tumours.

Psivida has been granted its fifth US patent for the classification of porous silicon into monodispersed particles with a tight size distribution.

Perth-based Solbec Pharmaceuticals (ASX:SBP) has paid a AUD$33,000 fine after being issued with an infringement notice by the Australian Securities and Investments Commission (ASIC) for allegedly failing to disclose information to the Australian Stock Exchange (ASX) relating to a drug trial.